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Oncogenic activity of SOX1 in 
glioblastoma
Idoia Garcia1,2,3, Juncal Aldaregia1, Jelena Marjanovic Vicentic4, Paula Aldaz1,3, Leire Moreno-
Cugnon1, Sergio Torres-Bayona5, Estefania Carrasco-Garcia1,3, Laura Garros-Regulez1, 
Larraitz Egaña1,5, Angel Rubio6, Steven Pollard7, Milena Stevanovic4, Nicolas Sampron1,3,5 & 
Ander Matheu1,2,3,5
Glioblastoma remains the most common and deadliest type of brain tumor and contains a population 
of self-renewing, highly tumorigenic glioma stem cells (GSCs), which contributes to tumor initiation 
and treatment resistance. Developmental programs participating in tissue development and 
homeostasis re-emerge in GSCs, supporting the development and progression of glioblastoma. SOX1 
plays an important role in neural development and neural progenitor pool maintenance. Its impact on 
glioblastoma remains largely unknown. In this study, we have found that high levels of SOX1 observed 
in a subset of patients correlate with lower overall survival. At the cellular level, SOX1 expression is 
elevated in patient-derived GSCs and it is also higher in oncosphere culture compared to differentiation 
conditions in conventional glioblastoma cell lines. Moreover, genetic inhibition of SOX1 in patient-
derived GSCs and conventional cell lines decreases self-renewal and proliferative capacity in vitro 
and tumor initiation and growth in vivo. Contrarily, SOX1 over-expression moderately promotes self-
renewal and proliferation in GSCs. These functions seem to be independent of its activity as Wnt/β-
catenin signaling regulator. In summary, these results identify a functional role for SOX1 in regulating 
glioma cell heterogeneity and plasticity, and suggest SOX1 as a potential target in the GSC population 
in glioblastoma.
Glioblastoma is the most common, aggressive and malignant adult brain tumor with an associated median sur-
vival of 15 months1. In recent years, several studies have provided a high-resolution picture of the genetic, epige-
netic, and transcriptomic landscape of glioblastoma, revealing a large number of genetic mutations and molecular 
alterations that drive disease pathogenesis and establishing this type of tumor into biologically and clinically 
distinct subgroups2,3. Notably, the expression of the identified subtype classifiers varies across individual cells 
within a tumor, indicating significant intratumoral heterogeneity in glioblastoma4. This heterogeneity is a major 
challenge for targeted therapy.
Increasing evidence indicates that several transcription factors directing developmental decisions can also 
function as oncogenes by promoting the reacquisition of developmental programs required for tumorigenesis5. 
Moreover, certain malignant tumors depend on a cellular hierarchy, with privileged subpopulations, called cancer 
stem cells (CSCs), driving tumor spread and growth. Thus, developmental programs, which participate in tissue 
development and repair regulating normal stem and progenitor cells, re-emerge in CSCs to support the develop-
ment and progressive growth of tumors5. Significant advances have been made in the identification of the molecu-
lar mechanisms underlying the pathobiology and intratumoral heterogeneity of glioblastoma4,6, however, further 
elucidation of the developmental programs governing glioma stem cells (GSCs) and glioblastoma progression 
is required in order to accelerate the development of urgently needed novel therapeutic targets and treatments.
SOX (sex-determining region Y (SRY)-box) genes are a family of transcription factors characterized by 
containing a conserved high-mobility group (HMG) DNA-binding domain. There are 20 members in humans 
divided into 8 groups based on their HMG sequence identity7. Members within the same group may have 
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overlapping expression patterns, share biochemical properties, and perform synergistic or distinct functions. 
SOX family members play crucial roles in both embryonic and postnatal development. They are also important 
for stem cell regulation and maintenance, particularly in the central nervous system8,9. There is a growing body 
of evidence that several SOX members are involved in cancer development. In general, they play a role in tumors 
arising in tissues overlapping with their expression pattern during embryonic development. Notably, some mem-
bers of the family are oncogenes while others act as tumor suppressors10. For example, SOX2, SOX4, SOX9 or 
SOX10 display oncogenic functions in different types of cancers including glioblastoma11–16. In contrast, SOX17 
and SOX11 have been shown to act as tumor suppressors in certain types of cancer such as gastrointestinal tum-
ors, mantle cell lymphomas, and also glioblastomas17–21.
SOX1 is a member of the SOXB1 subgroup, also containing SOX2 and SOX3. It is a well-established tumor sup-
pressor in ovarian, hepatocellular, cervical and nasopharyngeal cancers whose expression is commonly silenced 
by hypermethylation of its promoter region22–25. These findings are in agreement with the notion that promoter 
hypermethylation of tumor suppressor genes is an important contributor to carcinogenesis26. Mechanistically, 
SOX1 functions as a tumor suppressor through interaction with β -catenin, and consequent inhibition of the Wnt 
signaling pathway23,25. During development, members of the SOXB1 subgroup, show distinct and overlapping 
expression patterns. Sox1 is the earliest known specific marker of the neuroectoderm lineage, being activated 
during gastrulation. The other members, Sox2 and Sox3, show broader expression patterns turning on at the 
pre-implantation and epiblast stages, respectively27,28. In the brain, several reports have shown that Sox1 is a key 
regulator of neural progenitor identity and neural cell fate determination, maintaining the ability of these cells 
to either proliferate or differentiate from early development to adult stages28–31. Moreover, SOXB1 group mem-
bers are coexpressed in the neural stem cell population and show certain degree of functional redundancy8,32. 
Regarding the activity of SOXB1 members in glioblastoma, the oncogenic function and clinical relevance of SOX2 
is well established, most of its roles being linked to GSC regulation14,33–36. In contrast, little is known about the 
expression or function of SOX1 and SOX3. Interestingly, microarray analysis in SOX2 knockdown glioma cells 
identified SOX1 and SOX18 among the almost 500 genes whose expression was altered37, and this allowed us to 
hypothesize that SOX1 might have a role in glioblastoma. In this study, we explore this hypothesis finding that 
SOX1 is overexpressed in a subset of glioblastomas which present overall shorter patient survival. Moreover, we 
reveal that SOX1 is highly enriched in the pool of GSCs and its inactivation significantly impairs their malignant 
properties.
Material and Methods
Patients and tumor samples. Human glioblastoma samples were provided by the Basque Biobank for 
Research-OEHUN (http://www.biobancovasco.org). Data for GBM and LGG was downloaded using TCGA-
Assembler. The methods and experimental protocols in human samples were carried out in accordance with 
relevant guidelines, and all study participants signed the informed consent form. The study was approved by the 
ethic committee of Biodonostia Institute and Hospital Donostia.
Cell culture. Glioma cell lines T98, A172, U87, U373 and U251 were obtained from the ATCC. Cells were cul-
tured in DMEM (Gibco), supplemented with 10% fetal bovine serum (FBS), L-glutamine, penicillin and strepto-
mycin (Gibco). Patient-derived GNS166 and GNS179 cell lines, kindly provided by Dr. Steven Pollard38, GB1 and 
GB2, established by our group14, and oncospheres derived from cell lines were cultured in DMEM/F12 (Gibco) 
supplemented with N2 and B27 (Fisher), 40% glucose (Sigma), and growth factors b-FGF2, and EGF (Sigma). 
Differentiation assays were performed by removing bFGF and EGF and by adding 1%FBS to the DMEM-F12 
complete medium. To perform the spheres assay, 5 × 103 cells were plated per triplicate and grown in DMEM/F12 
complete medium for 10 days.
Viral infections. Lentiviral infection was performed as described previously using a multiplicity of infec-
tion of 10 for 6 h39. For this, pLM-mCitrine-SOX2 (SOX2) was received as a gift from Dr. Izeta40, pWPXL-SOX1 
(SOX1) was cloned by Dr. Stevanovic, and pLKO.1 shSOX1 (sh1 and sh5) were obtained from Sigma. Cells trans-
duced with pLKO.1 and shRNA plasmids were selected with 2 μ g/ml puromycin (Sigma) and maintained with 
0.2 μ g/ml puromycin.
Immunofluorescence. Immunofluorescence was performed following standard procedures14. The 
primary and secondary antibodies used were anti-phospho-histone H3 (p-H3, 1:2000; Ab14955, Abcam), 
β -catenin (1:250; 610153, BD transduction laboratories), anti-mouse Alexa Fluor 555 IgG (1:500 Invitrogen) and 
Cy3-streptavidin (1:5000, Jackson ImmunoResearch). Nuclear DNA staining and the mounting were performed 
with the Vectashield Hard set Mounting Medium with DAPI counterstain (Vector Laboratories). Pictures were 
taken in an Eclipse 80i microscope and processed with the NIS Elements Advanced Research Software (Nikon).
Cell viability MTT assay. 2 × 103 cells per well were seeded in sextuplicate and after 24 h, 0.5 mg/ml 
Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma) was added for 3 h at 37 °C. After the incubation, the content 
of the wells was removed and 150 μ l DMSO were added in order to dilute the formazan salt formed by viable 
cells. Absorbance was measured at 570 nm in a MultiSkan Ascent microplate reader (Thermo Scientific) using the 
Ascent software. Cellular viability of the shSOX1 cells was calculated relative to the absorbance of control cells.
RNA extraction, reverse transcription and gene expression. Total RNA was extracted using Tri 
Reagent solution (Life Technologies). Reverse transcription was performed using random primers and the 
MultiScribeTM Reverse Transcriptase Kit (Life Technologies). For qRT-PCR, 20 ng of cDNA was used to analyze 
gene expression with Absolute SYBR Green mix (Applied Biosystem), in a LightCycler 96 thermo-cycler (Roche). 
Transcript levels were normalized to GAPDH and measured using the Δ Δ Ct relative quantification method.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:46575 | DOI: 10.1038/srep46575
Immunohistochemistry. Tumors generated in mice were collected, fixed in 10% formalin for 48 h and 
embedded in paraffin. 4 μ m thick sections were deparaffinized, rehydrated and heated for 10 minutes in cit-
rate buffer for antigen retrieval. Endogenous peroxidase was blocked with 5% hydrogen peroxide in methanol 
for 15 min. After incubation with blocking solution, sections were incubated with the respective primary anti-
body anti-Ki67 (AB15580, Abcam), SOX1 (4194, Cell Signaling), SOX2 (AB5603, Millipore) and PML (A301–
167A, Bethyl Laboratories) at 37 °C for 2 hour. The sections were then washed and incubated with MACH 3 
Rabbit Probe and MACH 3 Rabbit HRP-Polymer (M3R531, Biocare Medical). Color was developed with 3,3′ 
Diaminobenzidine (DAB) and nuclei were counterstained with hematoxylin.
Western blot. Immunoblots were performed following standard procedures. The antibodies used in this 
study were anti-SOX1 (4194, Cell Signaling) and anti-SOX2 (AB5603, Millipore). Detection was performed by 
chemiluminescence using NOVEX ECL HRP Chemiluminescent Substrate Reagent Kit (WP20005, Invitrogen).
In vivo carcinogenesis. All animal handling and protocols were approved by the animal care ethic commit-
tee of Biodonostia Institute. For xenotransplantation, GSCs were injected stereotactically into the frontal cortex 
of 6 to 8 week-old NOD-SCID mice. Briefly, GSCs were disaggregated with accutase and resuspended in PBS. 
Approximately 1 × 105 cells were injected into the putamen using a stereotaxic procedure. Kaplan-Meier survival 
analysis was performed using the GraphPad Prism 5 software. For subcutaneous injection, glioma cells were har-
vested with trypsin/EDTA and resuspended in PBS. Approximately 5 × 105 and 5 × 104 cells were injected subcu-
taneously into both flanks of 8 week-old Foxn1nu/Foxn1nu nude mice. Mice were observed on a weekly basis and 
external calipers were used to measure tumor size, and from these measurements, tumor volume was estimated 
by V = L*W2*0.5; where L is the tumor length and W is the tumor width.
Data analysis. Results are represented as mean values ± standard error (SEM), indicating the number 
of experiments carried out for each assay. Statistical significance has been calculated using Student’s t-test, 
(*p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001), or the log-rank test for Kaplan Meier survival analyses.
Results
High SOX1 expression is associated with poor clinical outcome in glioblastoma. We analyzed 
the expression of SOX1 transcription factor in human clinical biopsies from brain tumors. First, we compared the 
expression of SOX1 in human low-grade glioma and normal brain samples. There were no differences between 
these two groups in The Cancer Genome Atlas (TCGA)6 publicly available datasets (Fig. 1A). Next, we investi-
gated SOX1 levels in a small glioblastoma cohort derived from Donostia Hospital. The expression of SOX1 in 
the tumor biopsies varied between 0.12 and 133 fold change when compared to normal brain tissue, with 18 of 
26 tumors showing greater than 1.5 fold change in SOX1 levels (Fig. 1B). We also studied SOX1 expression in 
the GBM data from the TCGA and found that its levels were also heterogeneous within the different samples 
(Fig. 1C). Notably, when we explored the correlation of SOX1 levels with clinical characteristics in the TCGA 
cohort, high SOX1 expression was associated with shorter overall survival (p = 0.02; Fig. 1D). Together, these 
results show that SOX1 expression is elevated in a subset of glioblastoma samples and its expression is a prognos-
tic biomarker.
SOX2 regulates the expression of SOX1 in glioblastoma. Since transcriptomic studies found SOX1 
within the list of genes down-regulated in SOX2-silenced LN229 glioma cells37, and we have recently observed 
that SOX2 activity modulates proliferation and self-renewal in glioma cells14, we investigated whether the 
expression of SOX1 was regulated by SOX2 in glioma. Notably, we found that SOX2-silenced U251 cells (with 
high endogenous SOX2 levels) displayed lower SOX1 levels than control cells (Fig. 1E,F). Contrarily, ectopic 
SOX2 overexpression in U87 cells (with low endogenous SOX2) significantly increased the expression of SOX1 
(Fig. 1E,F). To further study this putative correlation between SOX2 and SOX1, we moved to clinical biopsies, 
analyzing the expression of those transcription factors in the Donostia Hospital cohort of human glioblastoma 
samples. Interestingly, the correlation analysis showed a significant association between SOX2 and SOX1 expres-
sion (Fig. 1G). In fact, 60% of the biopsies with SOX2 overexpression also presented elevated levels of SOX1, 
whilst all of those with moderate or low SOX2 also had low SOX1 levels. These results indicate that there is a pos-
itive relationship between SOX2 and SOX1, it being likely that they act in the same signaling pathway.
GSCs express high levels of SOX1. We cultured several conventional glioma cell lines in different con-
ditions, growing them as adherent monolayers in the presence of serum (adherent) and as oncospheres in stem 
cell media. We first analyzed the expression levels of SOX1 in the adherent cells finding high levels in U251 and 
U373 cells, and low levels in U87, A172 and T98 cells (Fig. 2A). Interestingly, oncospheres derived from all five 
glioma cell lines had higher levels of SOX1 than observed in adherent cells (Fig. 2B). The latter culture condition 
was accompanied by increased expression of stem cell markers (SOX2, CD133, and OCT4) (Fig. 2C), which is 
consistent with an enrichment of stemness activity. Notably, we have previously shown that oncospheres, in line 
with their enhanced tumor-propagating activity, were associated with the formation of larger and faster-growing 
tumors14.
To further characterize the expression of SOX1, we moved onto primary GSCs derived from human patients, a 
model that is more similar and hence relevant to the clinical situation. We studied the levels of SOX1 expression in 
four independent GSC cultures detecting markedly higher levels in GSCs than the conventional glioma cell lines 
(Fig. 2D). Next, we investigated the relationship between SOX1 and the population of GSCs after differentiation 
of the four GSC primary cultures by removing the EGF and b-FGF2 growth factors and by adding serum. In this 
context, the levels of SOX1 decreased dramatically, by a mean of 70%, in all four cases (Fig. 2E). Similar results 
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were observed in SOX2, CD133 and OCT4 stem cell markers (Fig. 2F,G). These results demonstrate that SOX1 
levels are highly enriched in GSCs and correlate with the glioma cell undifferentiated condition.
SOX1 knockdown inhibits GSC activity. To directly explore the role of SOX1 in the activity of GSCs, we 
knocked-down SOX1 expression in a patient-derived cell line (GNS166) with two independent shRNAs. Effective 
inhibition of SOX1 was demonstrated with qRT-PCR when using both shSOX1 constructs (sh1 and sh5) (Fig. 3A). 
Functionally, SOX1 silencing promoted a significant decrease of more than 2-fold in cell growth rates (Fig. 3B). In 
line with this, MTT studies showed that the cell viability rate was also diminished in SOX1 silenced GNS166 cells 
Figure 1. High levels of SOX1 are associated to poor clinical outcome and correlate with SOX2.  
(A) Boxplot of the log2 of the FPKM of LGG (low grade glioma) vs normal brain samples in TGCA. Wilcoxon 
test, p value = 0.17. (B) SOX1 mRNA expression levels in GBM samples from Hospital Donostia and normal 
brain samples. (C) Boxplot of the log2 of the FPKM of glioblastoma vs normal brain samples in TGCA. The 
number of available RNAseq samples for glioblastoma is smaller than for LGG. Wilcoxon test, p value = 0.068. 
(D) Kaplan–Meier curves for the TCGA patient overall survival rates based on SOX1 expression obtained from 
cbioportal. LogRank Test p = 0.02. (E) SOX2 protein expression in U87 cells transduced with ectopic SOX2 
and U251 cells infected with shSOX2 and (F) SOX1 mRNA levels in the indicated cells. qRT-PCR data are 
normalized to GAPDH expression and are expressed relative to the control condition (n ≥ 3). (G) Analysis of 
the correlation of SOX2 and SOX1 expression in human glioblastoma samples. Fisher exact test p < 0.05.
www.nature.com/scientificreports/
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(Fig. 3C). These phenotypes correlated with a reduction in the number of the proliferative marker p-H3 positive 
cells (Fig. 3D). Specifically, we detected decrease in more than 70% of proliferating cells in sh1 and sh5 than in 
empty vector cells (Fig. 3D).
To further determine the impact of SOX1 regulating GSC self-renewal, we measured the expression of sev-
eral stem cell and differentiation markers. Notably, we observed a reduction in NESTIN, SOX2, SOX9 and PML 
stem cell markers (Fig. 3E), concomitantly with an increase in the expression levels of GFAP and p27Kip (Fig. 3F). 
Taken together, these results show that SOX1 plays a relevant role in GSC plasticity, via the regulation of the 
stemness-differentiation dichotomy.
The gold standard to identify the presence of GSC is to analyze the ability of the original patient tumor to 
replicate the tumor formation ability in vivo when transplanted orthotopically41. Therefore, NOD-SCID mice 
were intracranially injected with pLKO and sh1 GNS166 cells. Interestingly, SOX1 silencing significantly delayed 
tumor-forming capacity of GNS166 cells (Fig. 3G). Thus, the median survival for mice injected with pLKO cells 
was 27 weeks, whereas mice injected with sh1 cells survived a median of 42 weeks. These results indicate that 
SOX1 regulates GSCs self-renewal and tumorigenic activity.
Figure 2. SOX1 enrichment in glioma stem cell populations. (A) SOX1 mRNA levels in the indicated glioma 
cell lines showing different expression levels among them (n ≥ 3). (B) SOX1 levels in each cell line grown in 
stem cell medium (oncospheres) relative to in serum (adherent) (n ≥ 2). (C) mRNA levels of the indicated 
stem cell markers grown in serum and stem cell medium (n ≥ 2). (D) SOX1 expression levels in U87 and U251 
conventional cell lines and 4 patient derived GSC lines, the expression is relative to U87 cell line (n ≥ 3).  
(E) SOX1 levels in four GSC lines grown in stem cell medium (control) compared to differentiation conditions 
(diff) (n ≥ 2). (F,G) mRNA levels of the indicated stem cell markers grown in stem cell medium (control) 
compared to differentiation conditions (diff) in GNS and GB cells respectively (n ≥ 2). qRT-PCR data are 
normalized to GAPDH expression.
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SOX1 knockdown inhibits tumor initiation and progression in U251 glioma cells. In order to 
determine whether the mechanism by which SOX1 regulates proliferation and tumor growth is specific to GSCs 
or it is broader, we knocked-down SOX1 expression in the U251 cell line. Western blotting demonstrated effective 
inhibition of SOX1 at protein levels (Fig. 4A). Tumor-initiating ability in limiting dilution and oncosphere for-
mation studies functionally defines self-renewing CSCs in vivo and in vitro (Clevers CSCs premises). Therefore, 
we tested whether SOX1 silencing could regulate tumor initiation performing subcutaneous inoculation of 
serial diluted U251 cells transduced with empty vector or both shSOX1 constructs (sh1 and sh5) in immunode-
ficient mice and by performing oncosphere formation assays. Strikingly, the frequency of tumor initiating was 
1/1050263 in sh1 and 1/6359439 sh5 cells compared to 1/108183 in the empty vector harbouring cells (Fig. 4B). 
In line with these results, SOX1 silencing markedly decreased the ability of U251 cells to generate oncospheres 
(Fig. 4C). Moreover, at the molecular level, the silencing of SOX1 decreased PML and SOX2 expression (Fig. 4D), 
but up-regulated p27Kip levels (Fig. 4D). These results phenocopy the data obtained in GSCs and further reinforce 
that SOX1 silencing display a robust effect on blocking self-renewal and tumor initiation.
We further evaluated the role of SOX1 silencing in glioma cells. At the cellular level, cell counting studies 
revealed a significant reduction of 70% in cell growth rates in SOX1-silenced U251 cells (Fig. 4E). Moreover, the 
number of p-H3 positive cells was reduced by a mean of 90% and 50% in the case of sh1 and sh5 respectively, 
indicating that cell proliferation was dramatically impaired when SOX1 is down-regulated (Fig. 4F). Furthermore, 
there was a significant decrease in tumor growth in shSOX1 cells (Fig. 4G,H). Indeed, sh1 and sh5 cells formed 
subcutaneous tumors reaching less than 75 mm3 40 days after injection, while control tumors grew to an average 
of 550 mm3 in the same period of time (Fig. 4G). The impaired tumorigenic ability of shSOX1 cells was further 
corroborated by immunohistochemistry analysis in the tumors in vivo. Indeed, sh1 and sh5 derived xenografts 
Figure 3. SOX1 knockdown impairs self-renewal and tumor growth in GSCs. (A) SOX1 mRNA expression 
in control (pLKO) and shSOX1 (sh1 and sh5) GNS166 (n ≥ 2). (B) Cell growth at day 5 comparing pLKO and 
shSOX1 GNS166 cells (n = 3). (C) MTT studies measuring cell viability in shSOX1 relative to control GNS166 
cells (n = 3). (D) Representative image and quantification of number of p-H3 positive cells in pLKO and shSOX1 
transduced GNS166 cells (n = 3). (E) mRNA levels of the indicated stem cell markers in sh1 and sh5 GNS166 
cells relative to control expression (n ≥ 2). (F) GFAP and p27Kip mRNA levels in the indicated cell conditions 
(n ≥ 2). (G) Kaplan-Meier curve representing the survival of NOD-SCID mice that were xenotransplantated 
with control (n = 9) and sh1 (n = 4) GNS 166 cells.
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Figure 4. SOX1 knockdown in the U251 glioma cell line decreases tumor initiation and progression.  
(A) Representative western blotting of SOX1 protein expression in U251 cells infected with pLKO or sh1 (n = 3). 
(B) Frequency of tumor initiation after subcutaneous injection in nude mice of 5 × 105 and 5 × 104 U251 cells 
transduced with pLKO, sh1 or sh5. The incidence of tumor initiation was measured using the ELDA platform. 
(C) Quantification of the number of spheres formed from the indicated conditions (n = 3). (D) mRNA levels of 
the indicated genes in sh1 U251 cells relative to empty vector (n = 3). (E) Cell growth of U251 cells transduced 
with sh1 and sh5 relative to pLKO cells (n = 3). (F) Quantification of the number of p-H3 positive cells in the 
same conditions (n = 3). (G) Volume of tumors generated after subcutaneous injection of U251 pLKO, sh1 or 
sh5 cells (n = 12) at the indicated time-points. (H) Picture and average weight of the tumors generated in (G). 
(I) Representative images of the immunohistochemical staining of KI67, SOX1, SOX2 and PML in tumors from 
G (n = 4).
www.nature.com/scientificreports/
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possessed lower number of SOX1, Ki67, SOX2 and PML positive cells than tumors derived from control cells 
(Fig. 4I). In summary, SOX1 genetic silencing induces a strong tumor suppressor phenotype in glioma cells asso-
ciated with impaired self-renewal, proliferation, tumor initiation and progression.
SOX1 activity is not mediated by WNT/β-catenin signaling pathway. Since SOX1 acts as a tumor 
suppressor in different types of cancer through the Wnt/β-catenin signaling pathway (see introduction), we exam-
ined the activity of this pathway after silencing of SOX1 in glioma cells and GSCs. Immunofluorescence and 
immunohistochemistry of β -catenin did not show any clear difference in its expression and nuclear translocation 
between U251 cells transduced with empty vector or shSOX1 constructs (Fig. 5A,B). Moreover, qRT-PCR analysis 
in SOX1-silenced GNS166 cells did not show any significant modification in β-catenin and MYC expression levels 
(Fig. 5C), the latter being a well-established β-catenin downstream target39. To pursue the association between 
SOX1 and β -catenin, we turned into human patient biopsies. The results at cellular level were further confirmed 
in the datasets of TCGA cohort, where correlation analysis did not find association between SOX1 and β-catenin 
or MYC expression levels (Fig. 5D). These results suggest that the oncogenic activity of SOX1 is not mediated in 
glioblastoma cells by the β -catenin signaling pathway both at cellular level and in clinical samples.
We also studied the expression of CYCLIN D1, an additional β-catenin downstream target39. In this case, 
shSOX1 GNS166 cells presented diminished levels of CYCLIN D1 (Fig. 5C), and interestingly its expression sig-
nificantly correlated to SOX1 in the TCGA datasets (p < 0.005) (Fig. 5D). These results postulate CYCLIN D1 as a 
putative mediator of SOX1 activity in glioblastoma.
Figure 5. SOX1 is not regulating the WNT signaling pathway in glioblastoma. (A) Representative images 
of CTNNB1 (β -catenin) immunofluorescence staining in U251 plko and sh1 cells (n = 4). (B) Representative 
images of CTNNB1 immunohistochemical staining in U251 pLKO, sh1 and sh5 derived tumors (n = 4).  
(C) mRNA levels of CTNNB1, CCND1 (CYCLIN D1) and MYC in GNS166 pLKO and sh1 cells. qRT-PCR 
data are normalized to GAPDH expression (n ≥ 2). (D) Scatter plot of log2 of the FPKM of CTNNB1, MYC 
and CCND1 vs SOX1 expression. In the x-axis, the correlation and its statistical significance are included. Only 
CCND1 has a significant correlation with SOX1.
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Ectopic SOX1 overexpression promotes GSC proliferation and self-renewal. Finally, we intro-
duced a construct encoding SOX1 gene sequence in GNS166 cells. We confirmed the overexpression of SOX1 by 
Western blotting and q-RT PCR (Fig. 6A,B). In this context, SOX1 overexpression slightly increased the expres-
sion of SOX2 and PML stem cell markers (Fig. 6A,B), whilst decreased GFAP, CNPase and p27Kip levels (Fig. 6C). 
Phenotypically, cells with increased SOX1 expression exhibited moderately higher cell growth curves (Fig. 6D), 
and rates of proliferation compared to control cells (Fig. 6E). Collectively, this data revealed that elevated activity 
of SOX1 is not only necessary for the maintenance but might also promote proliferative and self-renewal activity 
in GSCs.
Discussion
Several transcription factors that direct developmental decisions might also act as oncogenes by promoting reac-
tivation of programs required for tumorigenesis5. SOX1 is a transcription factor that is essential for maintaining 
proliferation in the neural stem/progenitor pool, but its continued expression, leads to neuronal differentiation 
during development and adult stages42. Loss of SOX1 leads to epilepsy and eventual death though its absence 
is partially compensated for the other members of the SOXB1 subgroup, SOX2 and SOX3, with which shows 
overlapping expression patterns in neural stem/progenitor cells, and counteracts the activity of proneural pro-
teins28,32,43,44. Based on this evidence, SOX1 might be considered a key player in neural development through the 
maintenance of neural/progenitor pool homeostasis. Prior to this study, little was known about the impact of 
SOX1 in glioblastoma and in the maintenance of the GSC population. In this work, we have identified that SOX1 
displays oncogenic activity in glioblastoma by using several different approaches.
First, we investigated the expression of SOX1 in human brain samples. The analysis of SOX1 expression at 
mRNA level in a cohort of glioblastoma patients from Donostia Hospital indicated that SOX1 expression was 
slightly up-regulated in around 60% of tumor tissues compared to levels in healthy human brain samples. Taking 
advantage of the publicly available TCGA cohort data, we found that high levels of SOX1 in a subgroup of patients 
were associated with shorter patient survival. These data confirm the clinic-pathological and prognostic sig-
nificance of SOX1 expression, and, to our knowledge, it is the first evidence of high SOX1 expression level as 
Figure 6. SOX1 overexpression contributes to the malignant phenotype in GSCs. (A) SOX1 and SOX2 
protein expression in GNS166 cells transduced with ectopic SOX1 (n = 3). (B) mRNA levels of the indicated 
stem cell markers in GNS166 cells transduced with SOX1 relative to control (GFP) expression (n ≥ 3). (C) 
mRNA levels of the indicated differentiation markers in the same cells (n ≥ 3). (D) Cell growth at day 5 
comparing control (GFP) and SOX1 overexpressing GNS166 cells (n = 6). (E) Representative image and 
quantification of the number of p-H3 positive cells in SOX1 transduced GNS166 cells compared to control 
(GFP) condition (n = 6).
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a negative prognostic biomarker in cancer. In fact, low expression of SOX1 protein and/or mRNA expression 
was correlated with shorter overall survival and poor prognosis in ovarian cancer22, human hepatocellular car-
cinoma23,45, and esophageal squamous cell carcinoma46,47. These two sets of observations are not conflicting per 
se because it is conceivable that the expression of SOX1 could be elevated or decreased depending on the epige-
netic status or the cellular heterogeneity and plasticity. Regarding the epigenetic status, lower levels of SOX1 and 
better prognostic significance has been linked to the methylation of its promoter in several types of cancer23,25,46. 
Regarding cellular heterogeneity and plasticity, our data revealed that SOX1 expression is enriched in the popula-
tion of GSCs, grown in stem cell media, compared to parental cells, cultured in the presence of serum. Moreover, 
we found that patient-derived GSCs have higher levels of SOX1 expression than conventional cell lines, and these 
levels decrease when the GSCs are induced to differentiate in the presence of serum. These results demonstrate 
that high levels of SOX1 are linked to maintaining GSCs in an undifferentiated state. In agreement with this 
idea, SOX1 has been identified within the set of 19 neurodevelopmental transcription factors that are active and 
have higher expression in GSCs than in differentiated cells48. Furthermore, mapping of chromatin accessibility, 
before and after differentiation with BMP treatment, identified several enriched motifs for SOXB1 family mem-
bers, mostly SOX2 but also SOX1, as regulatory regions that failed to be completely silenced in GSC settings49. 
Moreover, SOX1 has been observed among the set of genes with elevated expression in CD44+ /CD24− and 
CD133+ breast cancer stem cells50 and in invasive prostate cancer cells, where SOX1 promoter was hypometh-
ylated51. Together, these results postulate that the enrichment of SOX1 in the population of CSCs is likely to be 
mediated by temporal and context dependent epigenetic changes. These findings are supported with the evidence 
that, during tumor initiation and progression, the epigenome of cancer cells goes through multiple alterations 
presenting broad domains of promoter hypermethylation, contributing to carcinogenesis through the inactiva-
tion of tumor suppressor genes and epigenetic regulators; but also including a genome-wide loss of DNA methyla-
tion (hypomethylation), likely affecting transcription factors which are important for self-renewal, and which are, 
therefore, under selective pressure to maintain or increase their expression in the corresponding cancer cell26,49,52.
Next, we studied the role of SOX1 in glioma cell activity through knockdown and overexpression assays. 
Experimental silencing of SOX1 directly in GSCs markedly reduced their proliferative and self-renewal activ-
ity, and delayed the formation of tumors when the cells were xenotransplanted into the brain. When the same 
approach was used with U251 cells, we obtained similar results. Indeed, SOX1 knockdown significantly impaired 
self-renewal and proliferative capability in vitro and tumor initiation and tumor progression in vivo. These results 
indicate that SOX1 expression is necessary for GSC maintenance likely regulating the interplay between prolifer-
ation, self-renewal and differentiation. On the contrary, SOX1 overexpression in GSCs moderately increased cell 
growth, proliferation and expression of stem cell markers. A complementary study showed that elevated SOX1 in 
differentiated glioma cells modestly enhanced sphere formation, and weakly induced the expression of the stem 
cell marker CD133 but failed to initiate tumors in mice that received an orthotopic xenograft48. These results 
support the notion that elevated expression of SOX1 is essential for maintaining, but not sufficient for promoting 
the self-renewal of GSCs. Several additional factors might cooperate to activate stem cell-like properties. Indeed, 
POU3F2, SOX2, SALL2, and OLIG2 have been shown to be the core set of transcription factors essential for GBM 
propagation, which are within the set of 19 transcription factors (including SOX1) required for successful repro-
gramming of differentiated glioma cells into GSCs48. In summary, our results firmly establish that SOX1 behaves 
as an oncogene in glioblastoma regulating glioma cell plasticity. This activity contrasts the evidence available 
for other types of cancers such as hepatocellular or nasopharyngeal carcinoma23,25, cervical24, lung53, or breast 
cancers54, in which it displays tumor suppressor activity. These data underline the fact that the activity of SOX1 is 
context dependent in cancer.
It has been previously shown that SOX1 is a negative regulator of WNT/β -catenin signaling in several types 
of cancer justifying its tumor suppressor activity. In glioblastoma, however, we have not detected any remarkable 
effects of SOX1 silencing on difference in the expression of β -catenin and its downstream target MYC at a cellular 
level in vitro, in tumors in vivo, as well as in clinical biopsies. Therefore, the oncogenic functions of SOX1 in glio-
blastoma seem to be β -catenin independent. Similar to these results SOX1overexpression in the embryonal tera-
tocarcinoma cell line, NT2/D1, did not affect the activity of WNT signaling55. At the molecular level, we detected 
that gain and silencing of SOX1 expression, in both GSC and U251 cell contexts, modulated the expression of the 
stem cell markers SOX2 and PML56–58, and well-established cell cycle regulators such as p27Kip and CYCLIN D159. 
These results suggest SOX2-PML and p27Kip-CYCLIN D1 as downstream molecular effectors by which SOX1 
functions in glioblastoma governing self-renewal and proliferation programs. Additional studies have shown that 
SOX1 alters SOX2 expression in human laryngeal squamous cell carcinoma60, regulates p27KIP levels in hepato-
cellular carcinoma23, and modulates CYCLIN D1 expression in hepatocellular and nasopharyngeal carcinoma as 
well as in breast cancer23,25,54. All together, data presented reinforce the relevance of those genes underlying SOX1 
activity. However, further work is needed to define their interactions in glioblastoma.
In summary, our work has identified that SOX1 expression is highly enriched in the pool of GSCs and its 
inactivation significantly impairs their malignant properties including proliferation, ability of self-renewal, dif-
ferentiation capacity as well as tumor initiation and progression. Based on our results, we postulate that SOX1 
is a master developmental transcription factor, governing and maintaining cellular plasticity and heterogene-
ity associated with diverse regulatory programs. Moreover, we reveal that SOX1 is overexpressed in a subset of 
glioblastoma human biopsies and that its high levels are associated with shorter overall patient survival. Taken 
together, our data pointed out to a previously unappreciated role for SOX1 as a central player to glioblastoma 
biology, prognosis, and therapy.
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